The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2026 | HC010, a PD-1/VEGF/CTLA-4 trispecific antibody, in advanced solid tumors
Yuxiang Ma, MD, PhD, Sun Yat-sen University Cancer Center, Guangzhou, China, highlights preliminary results from the first-in-human Phase I dose-escalation study (NCT06307925) of HC010, a trispecific antibody targeting PD-1, CTLA-4 and VEGF, in heavily pretreated patients with advanced solid tumors, most commonly non-small cell lung cancer (NSCLC). Encouraging efficacy signals were seen especially in immunotherapy-refractory patients and the drug showed a manageable safety profile and early antitumor activity across multiple tumor types. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved
Transcript
HC010 is a tumor-specific antibody. It’s an immunotherapy, immune checkpoint. And when we talk about antibodies with hormonal antibodies, and we are talking about the second generation of immune checkpoints, the bispecific antibody, the tumor-specific antibody. What I reported last month is a trispecific antibody. It inhibits the PD-L1, VEGF, and the CTLA-4. So it’s more like a combined drug for two immunotherapies and the VEGF...
HC010 is a tumor-specific antibody. It’s an immunotherapy, immune checkpoint. And when we talk about antibodies with hormonal antibodies, and we are talking about the second generation of immune checkpoints, the bispecific antibody, the tumor-specific antibody. What I reported last month is a trispecific antibody. It inhibits the PD-L1, VEGF, and the CTLA-4. So it’s more like a combined drug for two immunotherapies and the VEGF. So the preliminary results, the efficacy is nearly 20% of the patients have achieved partial remission. All these patients are pretty heavily treated and have shown good promising efficacy. And what is worth mentioning is that the PD marker is very good. The neutralization of VEGF in the circulation of peripheral blood is nearly 90% to 100% for the neutralization of VEGF and nearly 100% for the PD-L1 neutralization. So this drug, when we are doing the combination treatments we are currently doing now, the combination is ongoing, so we have very much confidence that this drug can be comparable or even better than the currently available biologic antibodies.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
